FDA Urges Device Manufacturers To Double-Check Their CAPA Systems
This article was originally published in The Silver Sheet
Executive Summary
WITH CORRECTIVE AND PREVENTIVE ACTION CITATIONS consistently showing up in FDA-483 forms and warning letters, the agency is urging medical device manufacturers to ensure that they are complying with all of the CAPA requirements in the Quality System Regulation. FDA experts offer tips on performing adequate complaint investigations, integrating risk management into the CAPA system, and performing adequate verification and validation of a corrective action... FROM WRITING GUIDANCES TO ANSWERING INDUSTRY CALLS, a workday at FDA’s device center is never routine. Compliance Officer Cap Uldriks tells how staff ensure projects get done...
You may also be interested in...
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
Thumbs Up: FDA Authorizes Weight Loss Suturing Systems From Apollo Endosurgery
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.
FDA Slaps High Risk Class I Label On Recall Of COVID-19 Diagnostics Made In Uncontrolled Plant
More than 160,000 of the tests were recalled, including 104,900 COVID Test Kits Nonsterile and 61,500 Clean Catch Urine Kits.